ZBBX_FLJ23049 Inhibitors
ZBBX_FLJ23049 inhibitors encompass a range of chemical compounds that attenuate the functional activity of the ZBBX_FLJ23049 protein by targeting various signaling pathways and cellular processes. Staurosporine, a broad-spectrum protein kinase inhibitor, can impede the phosphorylation necessary for ZBBX_FLJ23049's activity or its regulatory interactions. Similarly, LY 294002 and Rapamycin, by inhibiting PI3Ks and mTOR pathways, respectively, can disrupt the cellular growth and transcription factor activities that are crucial for ZBBX's role. Furthermore, kinase inhibitors such as PD 98059, SB 203580, and SP600125 target specific components of the MAPK/ERK, p38 MAPK, and JNK pathways, potentially curtailing ZBBX_FLJ23049 activity if these pathways are implicated in its regulation or functional engagement.
MG-132, by limiting proteasomal degradation, can modify the stability of proteins that may govern ZBBX_FLJ23049's function, while cyclopamine's antagonism towards the Hedgehog pathway can result in the reduction of ZBBX_FLJ23049 activity if it is intertwined with this signaling cascade. Additionally, the glucose uptake inhibitor WZB117 could impede the energy supply essential for ZBBX_FLJ23049's functions, and Brefeldin A, by hampering vesicle trafficking processes, could indirectly restrict ZBBX_FLJ23049 if its activity is contingent on proper cellular localization. U0126, another MEK1/2 inhibitor, could suppress ZBBX_FLJ23049 function by affecting MEK1/2-dependent signaling, and Trichostatin A, by altering gene expression patterns through histone acetylation modulation, may influence proteins that regulate or interact with ZBBX_FLJ23049, leading to a decrease in ZBBX_FLJ23049's functional activity. These inhibitors, despite their varied primary targets, converge on a common outcome of diminishing the functional activity of ZBBX_FLJ23049 by manipulating the cellular and molecular context in which ZBBX_FLJ23049 operates.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective protein kinase inhibitor. By inhibiting a broad range of kinases, it can indirectly lead to the decreased functional activity of ZBBX by disrupting the phosphorylation events that ZBBX might be involved in or that modulate its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks). Since PI3K signaling is involved in several cellular processes including transcription factor activity, LY 294002 can diminish ZBBX_FLJ23049 activity by inhibiting pathways that regulate its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress the mTOR pathway, which is involved in protein synthesis and cellular growth. Inhibition of this pathway can indirectly diminish ZBBX_FLJ23049 function by affecting the cellular contexts in which ZBBX_FLJ23049 operates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, PD 98059 can indirectly lead to a decrease in ZBBX_FLJ23049 activity if ZBBX_FLJ23049 is regulated by or interacts with proteins in the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. It can indirectly lead to the decreased functional activity of ZBBX_FLJ23049 if ZBBX_FLJ23049 is modulated by the p38 MAPK pathway or its downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in controlling gene expression linked to inflammation and apoptosis. Inhibition of JNK can diminish ZBBX_FLJ23049 activity if ZBBX_FLJ23049 is part of JNK-regulated signaling pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to decreased degradation of regulatory proteins, potentially influencing the cellular environment in which ZBBX_FLJ23049 operates. Inhibition of proteasome activity can indirectly affect ZBBX_FLJ23049 function by altering the stability of proteins that interact with or regulate ZBBX_FLJ23049. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine is an inhibitor of the Hedgehog (Hh) signaling pathway. If ZBBX_FLJ23049 is involved in the Hh pathway or is modulated by it, the inhibition of this pathway by cyclopamine can lead to decreased ZBBX_FLJ23049 functional activity. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 is an inhibitor of GLUT1, a glucose transporter. By inhibiting glucose uptake, WZB117 can decrease the energy supply required for ZBBX_FLJ23049-mediated functions, indirectly leading to its functional inhibition. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which plays a role in vesicle trafficking. By disrupting the secretory pathway, Brefeldin A can indirectly inhibit ZBBX_FLJ23049 if ZBBX_FLJ23049 requires vesicular transport for its function or localization. | ||||||